Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 228

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms

Stein, Rhona, Mattes, M. Jules, Cardillo, Thomas M., Hansen, Hans J., Chang, Chien-Hsing, Burton, Jack, Govindan, Serengulam, Goldenberg, David M. · 2007 · Clinical Cancer Research

Abstract

CD74 is an integral membrane protein that functions as a MHC class II chaperone. Moreover, it has recently been shown to have a role as an accessory-signaling molecule and has been implicated in malignant B-cell proliferation and survival. These biological functions combined with expression of CD74 on malignant B cells and limited expression on normal tissues implicate CD74 as a potential therapeutic target. The anti-CD74 monoclonal antibody LL1 has been humanized (hLL1 milatuzumab or IMMU-115) and can provide the basis for novel therapeutic approaches to B-cell malignancies, particularly because this antibody shows rapid internalization into CD74+ malignant cells. This article reviews the preclinical evaluations of LL1, its humanized form, and isotope, drug, and toxin conjugates. These studies show that unconjugated hLL1 and conjugates of hLL1 constructs with radioisotopes, doxorubicin, and frog RNase have high antitumor activity in non–Hodgkin's lymphoma and multiple myeloma in vitro and in tumor xenograft models. Single-dose studies of hLL1 in monkeys showed no adverse effects but did decrease circulating B and T lymphocytes and natural killer cells. When evaluated in combination with rituximab, either equivalent or improved efficacy, compared with either antibody alone, was observed. CD74 is a new candidate target for the immunotherapy of neoplasms expressing this antigen, which can be exploited using either a naked antibody or conjugated to isotopes, drugs, or toxins.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-07-1167

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 228

Metadata

Authors
Stein, R., Mattes, M. J., Cardillo, T. M., Hansen, H. J., Chang, C.-H., Burton, J., Govindan, S., & Goldenberg, D. M.
Venue
Clinical Cancer Research
Published
2007-09-15
Volume
13
Issue
18
Pages
5556s-5563s
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2168267840
Cited by
228
References
3
FWCI
7.25
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-07-1167
The paper
Stein, R., Mattes, M. J., Cardillo, T. M., Hansen, H. J., Chang, C.-H., Burton, J., Govindan, S., & Goldenberg, D. M. (2007). CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-07-1167

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.